Transcriptomics

Dataset Information

7

In silico analyses guides selection of BET inhibitors for triple negative breast cancer treatment


ABSTRACT: Triple negative breast cancer (TNBC) is an incurable disease with poor prognosis. At this moment, therapeutic options are limited to chemotherapy and no targeted agent has reached the clinical setting. Bromodomain and extraterminal (BET) inhibitors are a new family of compounds that inhibit bromodomain containing proteins affecting the expression of transcription factors (TFs), therefore modifying the expression of relevant oncogenic genes. We decided to performed gene-set enrichment analyses to get insights into the mechanism of action of these compounds. We treated cells with JQ1 and extracted RNA at 12 and 24 hours.

ORGANISM(S): Homo sapiens  

SUBMITTER: Alberto Ocaña   Javier Pérez-Peña  Javier Pérez Peña 

PROVIDER: E-GEOD-79476 | ArrayExpress | 2016-03-23

SECONDARY ACCESSION(S): GSE79476PRJNA315951

REPOSITORIES: GEO, ArrayExpress

Similar Datasets

2019-07-16 | PXD012060 | Pride
2015-05-01 | E-GEOD-66068 | ArrayExpress
2015-05-01 | E-GEOD-66122 | ArrayExpress
| GSE80527 | GEO
| GSE66122 | GEO
| GSE103068 | GEO
| GSE95476 | GEO
| PRJNA387217 | ENA
2014-09-29 | E-GEOD-53999 | ArrayExpress
2015-12-17 | E-GEOD-71185 | ArrayExpress